| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | GF1; GF-1; NFE1; XLTT; ERYF1; GATA-1; GATA1 |
| Entrez GeneID | 2623 |
| clone | 4G1 |
| WB Predicted band size | 42.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human GATA1 expressed in E. Coli. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是关于CCL25抗体的3-4篇假设性参考文献示例，内容基于典型研究方向构建：
1. **文献名称**：*Targeting CCL25 in Inflammatory Bowel Disease: A Novel Therapeutic Approach*
**作者**：Smith et al. (2021)
**摘要**：通过在小鼠结肠炎模型中应用抗CCL25单克隆抗体，研究发现中和CCL25可显著减少肠道炎症反应和CD8+ T细胞的异常浸润，证实CCL25是炎症性肠病(IBD)的潜在治疗靶点。
2. **文献名称**：*CCL25/CCR9 Axis Promotes Colorectal Cancer Metastasis via Immune Modulation*
**作者**：Zhang et al. (2020)
**摘要**：该研究利用抗CCL25抗体阻断CCL25/CCR9信号通路，发现可抑制结直肠癌肝转移并增强肿瘤微环境中效应T细胞的活性，为免疫联合治疗提供新策略。
3. **文献名称**：*Role of CCL25 in T Cell Homing to the Gut-Associated Lymphoid Tissue*
**作者**：Johnson et al. (2019)
**摘要**：通过抗体介导的CCL25功能抑制实验，揭示了CCL25在调控肠道特异性T细胞归巢中的核心作用，阐明了其在黏膜免疫稳态中的机制。
4. **文献名称**：*Anti-CCL25 Antibody Therapy Attenuates Allergic Inflammation in a Murine Asthma Model*
**作者**：Lee et al. (2022)
**摘要**：研究显示，抗CCL25抗体通过抑制Th2型细胞因子的产生和嗜酸性粒细胞募集，显著缓解小鼠哮喘模型的气道高反应性，拓展了CCL25抗体在过敏性疾病中的应用前景。
**注**：以上文献为假设性示例，实际引用时需通过学术数据库(如PubMed、Web of Science)检索真实发表的论文。
**Background of CCL25 Antibodies**
CCL25 (C-C motif chemokine ligand 25), also known as thymus-expressed chemokine (TECK), is a small cytokine belonging to the CC chemokine family. It binds specifically to the CCR9 receptor, playing a critical role in directing immune cell migration, particularly in mucosal tissues. CCL25 is predominantly expressed in the thymus and small intestine, where it regulates the homing of T lymphocytes, dendritic cells, and IgA-secreting plasma cells to gut-associated lymphoid tissues (GALT). This chemokine-receptor axis (CCL25-CCR9) is essential for maintaining intestinal immunity and tolerance.
Antibodies targeting CCL25 are valuable tools for studying its biological functions and therapeutic potential. They are designed to block CCL25-CCR9 interactions, enabling researchers to investigate mechanisms underlying inflammatory bowel diseases (e.g., Crohn’s disease), autoimmune disorders, and cancer metastasis. For instance, CCL25 overexpression has been linked to colorectal cancer progression, as it may promote tumor cell survival and invasion via CCR9 signaling.
Monoclonal and polyclonal CCL25 antibodies are widely used in immunoassays (ELISA, flow cytometry), immunohistochemistry, and functional studies. Therapeutic applications are also being explored, with preclinical studies suggesting that neutralizing CCL25 antibodies could mitigate pathological inflammation or disrupt cancer cell trafficking. However, clinical translation remains in early stages, necessitating further research to validate efficacy and safety. Overall, CCL25 antibodies serve as crucial reagents for dissecting immune regulation and developing targeted therapies.
×
